L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. JP Vacca, BD Dorsey, WA Schleif, RB Levin, SL McDaniel, PL Darke, ... Proceedings of the national academy of sciences 91 (9), 4096-4100, 1994 | 695 | 1994 |
L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor BD Dorsey, RB Levin, SL McDaniel, JP Vacca, JP Guare, PL Darke, ... Journal of medicinal chemistry 37 (21), 3443-3451, 1994 | 545 | 1994 |
Knowledge-based, central nervous system (CNS) lead selection and lead optimization for CNS drug discovery AK Ghose, T Herbertz, RL Hudkins, BD Dorsey, JP Mallamo ACS chemical neuroscience 3 (1), 50-68, 2012 | 394 | 2012 |
A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site MK Holloway, JM Wai, TA Halgren, PMD Fitzgerald, JP Vacca, BD Dorsey, ... Journal of medicinal chemistry 38 (2), 305-317, 1995 | 309 | 1995 |
Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer BD Dorsey, M Iqbal, S Chatterjee, E Menta, R Bernardini, A Bernareggi, ... Journal of medicinal chemistry 51 (4), 1068-1072, 2008 | 178 | 2008 |
HIV protease inhibitors useful for the treatment of AIDS JP Vacca, BD Dorsey, JP Guare, MK Holloway, RW Hungate, RB Levin US Patent 5,413,999, 1995 | 164 | 1995 |
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells W Wan, MS Albom, L Lu, MR Quail, NC Becknell, LR Weinberg, ... Blood 107 (4), 1617-1623, 2006 | 157 | 2006 |
Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines CS Burgey, KA Robinson, TA Lyle, PEJ Sanderson, SD Lewis, BJ Lucas, ... Journal of medicinal chemistry 46 (4), 461-473, 2003 | 128 | 2003 |
Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates PEJ Sanderson, TA Lyle, KJ Cutrona, DL Dyer, BD Dorsey, ... Journal of medicinal chemistry 41 (23), 4466-4474, 1998 | 122 | 1998 |
Anti-cancer agents and uses thereof M Kelly, Y Lee, B Liu, T Fujimoto, J Freundlich, BD Dorsey, GA Flynn, ... US Patent App. 11/819,494, 2008 | 117 | 2008 |
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis KL Stump, LD Lu, P Dobrzanski, C Serdikoff, DE Gingrich, BJ Dugan, ... Arthritis research & therapy 13, 1-15, 2011 | 105 | 2011 |
Identification of 1-(3-(6, 7-dimethoxyquinazolin-4-yloxy) phenyl)-3-(5-(1, 1, 1-trifluoro-2-methylpropan-2-yl) isoxazol-3-yl) urea hydrochloride (CEP-32496), a highly potent … MW Rowbottom, R Faraoni, Q Chao, BT Campbell, AG Lai, E Setti, ... Journal of medicinal chemistry 55 (3), 1082-1105, 2012 | 95 | 2012 |
Discovery of clinical candidate CEP-37440, a selective inhibitor of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK) GR Ott, M Cheng, KS Learn, J Wagner, DE Gingrich, JG Lisko, M Curry, ... Journal of medicinal chemistry 59 (16), 7478-7496, 2016 | 83 | 2016 |
Benzodiazepines as potent and selective bradykinin B1 antagonists MR Wood, JJ Kim, W Han, BD Dorsey, CF Homnick, RM DiPardo, ... Journal of medicinal chemistry 46 (10), 1803-1806, 2003 | 83 | 2003 |
Anti-cancer agents and uses thereof M Kelly, BD Dorsey, GA Flynn US Patent 7,504,401, 2009 | 82 | 2009 |
Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1 JJ Park, EP Thi, VH Carpio, Y Bi, AG Cole, BD Dorsey, K Fan, T Harasym, ... Nature Communications 12 (1), 1222, 2021 | 79 | 2021 |
A Selective, Orally Bioavailable 1,2,4-Triazolo[1,5-a]pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779 BJ Dugan, DE Gingrich, EF Mesaros, KL Milkiewicz, MA Curry, AL Zulli, ... Journal of medicinal chemistry 55 (11), 5243-5254, 2012 | 79 | 2012 |
Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2 LD Lu, KL Stump, NH Wallace, P Dobrzanski, C Serdikoff, DE Gingrich, ... The Journal of Immunology 187 (7), 3840-3853, 2011 | 76 | 2011 |
CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers M Cheng, MR Quail, DE Gingrich, GR Ott, L Lu, W Wan, MS Albom, ... Molecular cancer therapeutics 11 (3), 670-679, 2012 | 74 | 2012 |
L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor PEJ Sanderson, KJ Cutrona, BD Dorsey, DL Dyer, CM McDonough, ... Bioorganic & medicinal chemistry letters 8 (7), 817-822, 1998 | 68 | 1998 |